Literature DB >> 3034178

Unusual neurotoxicity associated with amiodarone therapy.

P R Palakurthy, V Iyer, R J Meckler.   

Abstract

One hundred two patients with recurrent, drug-refractory tachyarrhythmias were treated with amiodarone for nine +/- eight months (mean +/- SD) (range, one to 50 months). Forty-five patients exhibited some form of neurotoxic reaction that was severe enough in nine patients to require discontinuation of treatment or reduction in dosage of the drug. The most frequent neurotoxic findings were tremor (44 patients), peripheral neuropathy (ten patients), and ataxia (seven patients). Five patients developed unusual neurotoxic manifestations: brainstem dysfunction characterized by downbeat nystagmus, hemisensory loss and ataxia, severe dyskinesia, jaw tremor, and proximal myopathy. Neurophysiologic studies revealed varying degrees of predominantly demyelinating peripheral neuropathy. Neurotoxic symptoms improved after discontinuing treatment or decreasing the dosage of the drug. Age of the patient and total cumulative dose did not seem to be risk factors for development of neurotoxicity. These neurotoxic findings suggest that amiodarone-induced neurotoxic reactions are not only confined to the peripheral nervous system, but also that parts of the central nervous system (eg, basal ganglia, brain stem, or their connections) may also be involved.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3034178

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  13 in total

Review 1.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

2.  'White elephants' and a distinguished monkey - or the need for a proactive follow-up in amiodarone therapy.

Authors:  Chr van Tellingen
Journal:  Neth Heart J       Date:  2004-10       Impact factor: 2.380

3.  Unusual amiodarone toxicity in a child.

Authors:  Bahram Kakavand; Thomas G Di Sessa
Journal:  J Pediatr Pharmacol Ther       Date:  2008-04

4.  Ataxia: a diagnostic perplexity and management dilemma.

Authors:  Vinod K Chaubey; Lovely Chhabra; Aaysha Kapila
Journal:  BMJ Case Rep       Date:  2013-09-26

Review 5.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 6.  Sensory neuropathies including painful and toxic neuropathies.

Authors:  J H Wokke; G W van Dijk
Journal:  J Neurol       Date:  1997-04       Impact factor: 4.849

7.  Analysis of computed tomography density of liver before and after amiodarone administration.

Authors:  Masazumi Matsuda; Aoi Otaka; Tomoki Tozawa; Tomoyuki Asano; Koichi Ishiyama; Manabu Hashimoto
Journal:  Jpn J Radiol       Date:  2018-04-02       Impact factor: 2.374

8.  Amiodarone and desethylamiodarone increase intrasynaptosomal free calcium through receptor mediated channel.

Authors:  P R Kodavanti; S N Pentyala; P R Yallapragada; D Desaiah
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

9.  Lipidosis of the dorsal root ganglia in rats treated with an almitrine metabolite.

Authors:  Y Yamanaka; E Sakamoto; Y Sakuma; H Uno; T Koyama; Y Izawa; K Fujiwara
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

10.  Predictors of the risk of falls among elderly with chronic atrial fibrillation.

Authors:  Angela Cristina Silva dos Santos; Moacyr Roberto Cucê Nobre; Amit Nussbacher; Giselle Helena de Paula Rodrigues; Otavio Celso Eluf Gebara; João Batista Carvalho Serro Azul; Mauricio Wajngarten
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.